Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02680756
• Date of registration: 09/02/2016
• Prospective Registration: No
• Primary sponsor: Shield Therapeutics
• Public title: Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
• Scientific title: A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease
• Date of first enrolment: January 2016
• Target sample size: 250
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02680756
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 3

Countries of recruitment

Belgium, France, Germany, Hungary, Spain, United States

Contacts

• Name: Jackie Mitchell, PhD
• Affiliation: Shield Therapeutics

Key inclusion & exclusion criteria

All of the following criteria must be met to randomize a subject in the study:

1. Subjects must be competent to understand the information given in the Independent
Ethics Committee (IEC) or Institutional Review Board (IRB) approved informed consent
form and must sign and date the informed consent prior to any study mandated procedure

2. Subjects must be willing and able to comply with study requirements

3. Age = 18 years

4. Subjects must have a confirmed diagnosis of IBD (endoscopic and/or biopsy)

5. Subjects must be considered suitable for intravenous iron treatment by the
Investigator

6. Subjects must have iron deficiency anaemia defined by the following criteria:

1. Hb 8.0 g/dL and =11.0 g/dL for women OR a Hb 8.0 g/dL and =12.0 g/dL for men

2. AND Ferritin <30ng/ml OR Ferritin <100 ng/ml WITH Transferrin saturation (TSAT)
<20%

7. Female subjects of childbearing potential (including perimenopausal females who have
had a menstrual period within 1 year prior to screening) must agree to use a reliable
method of contraception until they have completed the study and for at least 4 weeks
following their final study visit. Reliable contraception is defined as a method which
results in a low failure rate, i.e., less than 1% per year when used consistently and
correctly, such as implants, injectables, some intrauterine contraceptive devices
(IUDs), complete sexual abstinence, or a vasectomized partner. Oral contraceptive
medications are allowed in this study. Female subjects who are surgically sterile
(bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or postmenopausal
(defined as no menstrual period within 1 year of screening) are also allowed to
participate.

A subject who meets any of the following criteria is not eligible for participation in the
study.

1. Subject with anaemia due to any cause other than iron deficiency, including, but not
limited to:

1. Untreated or untreatable severe malabsorption syndrome

2. Immunosuppressant use. Immunosuppressants are permitted so long as there is no
clinical evidence or suspicion of the immunosuppressant contributing to the
subject's anaemia or affecting erythropoiesis.

Variations to dosing are permitted at the discretion of the investigator so long as
there is no clinical evidence or suspicion of the immunosuppressant contributing to
the subject's anaemia or affecting erythropoiesis

2. Subject who has received prior to screening:

1. Within 8 weeks intramuscular or intravenous (IV) iron or administration of depot
iron preparation

2. Within 2 weeks a blood transfusion

3. Oral iron supplementation, taken specifically to treat anaemia, within the
previous 4 weeks (Over the Counter (OTC) multivitamins containing iron are
permitted)

3. Subjects with active inflammatory bowel disease as defined by a SCCAI score greater
than 5 at Screening or a CDAI score greater than 300 in the Screening period (as
assessed using the Screening haematocrit (HCT) and CDAI diary card completed by the
subject for 7 days prior to planned randomization).

4. Subjects with known hypersensitivity or allergy to either the active substance or
excipients of ferric maltol capsules or ferric carboxymaltose solution for IV
administration

5. Subjects who have had serious adverse reactions to previous doses of ferric
carboxymaltose or any other intravenous iron.

6. Subjects with contraindication for treatment with iron preparations, e.g.
hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or
lead intoxication induced anaemia.

7. Subjects with vitamin B12 or folic acid deficiency as determined by the central
laboratory screening results. Subjects may start vitamin B12 or folate replacement and
rescreen after at least 2 weeks.

8. Subjects who are pregnant or breast feeding.

9. Concomitant medical conditions with significant active bleeding likely to initiate or
prolong anaemia.

10. Participation in any other interventional clinical study within 30 days prior to
screening.

11. Subject with cardiovascular, liver, renal, haematologic, gastrointestinal,
immunologic, endocrine, metabolic, or central nervous system disease that, in the
opinion of the Investigator, may adversely affect the safety of the subject or
severely limit the lifespan of the subject (i.e. unlikely to complete the full
duration of the study).

12. Subject with significant neurologic or psychiatric symptoms resulting in
disorientation, memory impairment, or inability to report accurately that might
interfere with treatment compliance, study conduct or interpretation of the results
(e.g., Alzheimer's disease, schizophrenia or other psychosis, active or current
alcohol or drug abuse)

13. Subject who is an inmate of a psychiatric ward, prison, or other state institution.

14. Subject who is an Investigator or any other team member involved directly or
indirectly in the conduct of the clinical study.

15. Subjects with severe renal impairment: creatinine clearance <30 mL/min. (Applicable to
US sites Only)



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Crohn's Disease

Anemia, Iron-Deficiency

Inflammatory Bowel Disease

Intervention(s)

Drug: Ferric Carboxy Maltose

Drug: Ferric Maltol

Primary Outcome(s)

Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12 [Time Frame: Baseline to Week 12]

Secondary Outcome(s)

Change in Hb Concentration From Baseline to Week 12 [Time Frame: Baseline to Week 12]

Number of Subjects Who Experience a Change From Baseline in Hb Concentration =1.0 g/dL at Week 4 [Time Frame: Baseline to Week 4]

Number of Subjects Who Experience a Change From Baseline in Hb Concentration =2.0 g/dL at Week 12 [Time Frame: Baseline to Week 12]

Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb <9.5 g/dL [Time Frame: Baseline to Week 4]

Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of =2 g/dL at Week 12 [Time Frame: Baseline to Week 12]

Number of Subjects With Hb Concentration Within Normal Limits at Week 4 [Time Frame: Baseline to Week 4]

Proportion of Subjects Who Are Non-anaemic at 6 Months and 12 Months [Time Frame: Baseline to Month 6]

Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of =1 g/dL at Week 12 [Time Frame: Baseline to Week 12]

Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 12 [Time Frame: Baseline to Week 12]

Number of Subjects Who Experience a Change From Baseline in Hb Concentration =2.0 g/dL at Week 4 [Time Frame: Baseline to Week 4]

Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of =1 g/dL at Week 4 [Time Frame: Baseline to Week 4]

Number of Subjects Who Experience a Change From Baseline in Hb Concentration =1.0 g/dL at Week 12 [Time Frame: Baseline to Week 12]

Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb <9.5 g/dL [Time Frame: Baseline to Week 12]

Number of Subjects With Hb Concentration Within Normal Limits at Week 12 [Time Frame: Baseline to Week 12]

Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 4 [Time Frame: Baseline to Week 4]

Change in Hb Concentration From Baseline to Week 4 [Time Frame: Baseline to Week 4]

Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of =2 g/dL at Week 4 [Time Frame: Baseline to Week 4]

Secondary ID(s)

ST10-01-304

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 24/02/2020
• URL: https://clinicaltrials.gov/ct2/show/results/NCT02680756